MedPath

Clinical effect of point application combined with desomumab in the treatment of postmenopausal osteoporosis

Phase 1
Conditions
Postmenopausal osteoporosis
Registration Number
ITMCTR2200006016
Lead Sponsor
The Second Affiliated Hospital of Zhejiang Chinese Medicine University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Female
Target Recruitment
Not specified
Inclusion Criteria

? Through bone mineral density examination, according to the lumbar bone mineral density (BMD) measured by DXA, lumbar T=-2.5SD.
? The patient has normal menopause and has been menopausal for more than 5 years;
? Female patients aged between 50 and 80 years old;
? Those who are willing to be subjects, can guarantee to complete the treatment course and sign informed consent.

Exclusion Criteria

? Does not meet the diagnostic criteria of osteoporosis;
? Diabetes mellitus, thyroid or parathyroid functional changes, osteomalacia, rheumatoid arthritis, multiple myeloma, bone tumors, Paget's disease, osteogenesis imperfection and other diseases that seriously affect bone metabolism;
? Uterus and ovaries removed;
(4) those who have used hormones, calcitonin or other drugs affecting bone metabolism within six months;
? Patients with serious cardiovascular and cerebrovascular diseases or liver and kidney failure;
? Other diseases and factors that can cause secondary osteoporosis.
Patients with a history of severe skin allergy or skin sensitivity

Study & Design

Study Type
Interventional study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Bone mineral density;
Secondary Outcome Measures
NameTimeMethod
TCM clinical symptom score;Bone metabolic index;
© Copyright 2025. All Rights Reserved by MedPath